Combining the PLG scaffold DC vaccine with anti-cytotoxic T lymphocyte-associated protein 4 antibodies (CTLA-4) antibodies showed promising tumor regression and CTL activity, preventing multiple scaffold administrations [25, 39]. The gene discussed is CTLA4; the disease is neoplasm.